| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:e68.)
© 2004 American Heart Association, Inc.
Research Reports |
From the Department of Cardiology, University Hospital, Basel, Switzerland.
Correspondence to Professor S. Osswald, FESC, FACC, Department of Cardiology, University Hospital, CH-4031 Basel, Switzerland. E-mail sosswald{at}uhbs.ch
| Abstract |
|---|
|
|
|---|
Methods Retrospective evaluation of all Holter ECGs in patients with cerebral ischemic events was done. Chart analysis with regard to drug treatment modification and cardiovascular drug therapy was performed in all patients.
Results Between January 2000 and December 2002, 425 hospitalized patients (median age, 68 years) had routine Holter ECG after a cerebral ischemic event. PAF was diagnosed in 9 patients (2.1%): in 2, oral anticoagulation was contraindicated; 1 had severe carotid stenosis as an additional risk factor; 1 had PAF but was on oral anticoagulation for basilar thrombosis; 2 had had PAF before and were on aspirin; and 3 had a new diagnosis of PAF. The last 5 patients were put on oral anticoagulation. Thus, routine Holter ECG resulted in drug treatment modification in only 5 of 425 patients (1.2%).
Conclusions PAF in cerebral ischemic event patients has a low incidence and, if diagnosed, rarely leads to drug modification. Therefore, routine Holter monitoring for PAF screening is not recommended in this patient population.
Key Words: electrocardiography, ambulatory paroxysmal atrial fibrillation risk assessment stroke
| Introduction |
|---|
|
|
|---|
The aim of the present study was therefore to evaluate the incidence of PAF in stroke patients as diagnosed by a single 24-hour Holter ECG and its impact on subsequent patient management regarding DTM.
| Materials and Methods |
|---|
|
|
|---|
Holter ECGs were performed on a SCHILLER MT-200 system (Schiller AG) and independently analyzed by 2 cardiologists. Monitoring time was 24 hours.
Definitions
According to current guidelines,10 PAF is defined as a self-terminating sequence of >30 seconds of irregular RR intervals and the presence of fibrillatory P waves. Persistent AF is defined as nonself-terminating AF that can be converted to sinus by either drugs or direct current shock. Permanent AF is defined as AF in which conversion to sinus failed or was not attempted. Atrial bursts were defined as irregular beats with fibrillatory waves lasting <30 seconds. Regular supraventricular bursts (suggestive of AV nodal reentrant or ectopic atrial tachycardias) were not qualified as PAF. DTM was defined as initiation of oral anticoagulation (OAC) with Coumadin derivates or switch from aspirin/clopidogrel to OAC.
Statistical Analysis
Comparisons between groups were performed by use of 1-way analysis of variance for continuous variables that are described as mean±SD. A value of P<0.05 was considered statistically significant. Statistical analysis was done with StatView software, version 5 (SAS).
| Results |
|---|
|
|
|---|
|
In 9 patients (2.1%), PAF was newly diagnosed. Their characteristics are shown in Table 2. Five patients had episodes terminating during Holter ECG, 2 had no AF in all available 12-lead ECGs but AF during the complete Holter ECG, and 2 had AF beginning during and lasting until the end of the Holter ECG. Patients with PAF were older (72.6±9.4 years) compared with non-PAF patients (67.3±12.0, P=NS), and no PAF patient was <55 years of age. No patient had atrial flutter.
|
Results of Holter ECG led to DTM in 5 patients (1.2%). OAC was started in 3 patients (patients 4, 6, and 8), and 2 (patients 2 and 9) were switched from aspirin to OAC. OAC could not be discontinued in any of the 22 patients on OAC at the time of Holter ECG because of negative Holter ECG (other reasons for OAC such as mechanical heart valves and recurrent deep vein thrombosis).
The number of Holter ECGs performed for a diagnosis of PAF was 47. For one DTM, 85 Holter ECGs were performed.
With Holter ECG costs of $200, overall costs were $85 000, $9400 for the diagnosis of a case of PAF, and $17 000 for 1 DTM.
| Discussion |
|---|
|
|
|---|
Although the prognostic impact of PAF is not known, Holter ECG has become a routine procedure in the evaluation of CIE patients. Because cost-effectiveness has become a major issue, it is important to question the impact of such routine procedures. Unfortunately, evidence regarding the value of Holter ECG in this setting is limited. Studies investigating the incidence of PAF in stroke patients were published between 1982 and 199649 and included 150 patients at the most. PAF incidence was between 3.3%9 and 24.4%.4 Summing up all those patients, the incidence was 7.6% (62 of 817). Moreover, in 2 studies including 250 patients,5,7 PAF was known by history or 12-lead ECG in 14 of 15 PAF patients. Unfortunately, only one study8 mentioned a definition of PAF ("lasting longer than 5 minutes"). In all these studies, the rate of DTM as a consequence of the Holter ECG results was not evaluated.
In our study with a concise definition of PAF, the incidence of true PAF (no AF in any available 12-lead ECG) was only 2.1%. Because 2 patients had contraindications for anticoagulation, 1 was on anticoagulation for an coincidental basilar thrombosis and 1 had severe carotid artery stenosis (that was probably the cause of the stroke and later operated on), only 5 patients (1.2%) had DTM as a consequence of all 425 Holter ECGs performed.
Because there is no clear evidence for how to treat PAF with regard to anticoagulation (eg, current guidelines10 of the European Society of Cardiology do not mention PAF), it must be questioned whether results do or should influence clinical management of patients at all.
It might well be that the incidence of PAF is underestimated with Holter ECG and that a prolonged or automated monitoring would provide a higher yield regarding PAF incidence. Recently, promising results were shown with a computer-derived analysis of heart rate intervals,15 but few patients were studied, and the setting was not that of CIE patients.
Study Limitations
One bias could be that CIE patients with obvious risk factors for stroke (eg, severe carotid stenosis or artificial heart valves with poor OAC) were not referred for Holter ECG. This could have influenced the detected rate of PAF in both ways but not the rate of DTM. Another limitation might be that with a monitoring period >24 hours, more episodes of PAF would have been detected, but so far, 24-hour monitoring is recognized as the standard period.
Conclusions
Our study showed that routine Holter ECG has little value for the clinical management in stroke patients because the incidence of PAF is low and the impact of its diagnosis on the antithrombotic therapy is uncertain. Furthermore, data on the long-term effect of anticoagulation in these patients and clear-cut guidelines are missing. Therefore, we do not recommend Holter ECG as a routine procedure after CIEs.
| Footnotes |
|---|
Received November 3, 2003; accepted December 3, 2003.
| References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |